United Therapeutics (UTHR) Lowered to “Strong Sell” at BidaskClub

United Therapeutics (NASDAQ:UTHR) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports.

UTHR has been the subject of several other research reports. Oppenheimer set a $160.00 target price on United Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 26th. Barclays dropped their target price on United Therapeutics from $100.00 to $95.00 and set an “underweight” rating for the company in a research report on Friday, March 1st. Cowen reiterated a “hold” rating and issued a $109.00 price target on shares of United Therapeutics in a report on Wednesday, February 27th. TheStreet upgraded United Therapeutics from a “c+” rating to a “b-” rating in a report on Monday, February 11th. Finally, ValuEngine upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $132.89.

Shares of NASDAQ:UTHR traded down $1.17 during trading hours on Wednesday, hitting $89.33. 649,159 shares of the company’s stock traded hands, compared to its average volume of 436,571. United Therapeutics has a 1 year low of $88.25 and a 1 year high of $130.00. The firm has a market capitalization of $3.91 billion, a PE ratio of 6.67 and a beta of 1.01. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The business had revenue of $362.70 million for the quarter, compared to analysts’ expectations of $335.72 million. During the same quarter last year, the firm earned $3.76 EPS. The firm’s quarterly revenue was down 6.8% on a year-over-year basis. Equities research analysts expect that United Therapeutics will post -5.03 EPS for the current fiscal year.

In related news, Director Christopher Patusky sold 3,370 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total value of $373,227.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.20% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Unison Advisors LLC purchased a new stake in United Therapeutics during the first quarter worth $205,000. IFM Investors Pty Ltd lifted its holdings in United Therapeutics by 12.2% during the fourth quarter. IFM Investors Pty Ltd now owns 2,644 shares of the biotechnology company’s stock worth $288,000 after buying an additional 288 shares during the period. BB&T Corp lifted its holdings in United Therapeutics by 2.3% during the fourth quarter. BB&T Corp now owns 10,996 shares of the biotechnology company’s stock worth $1,197,000 after buying an additional 246 shares during the period. First Citizens Bank & Trust Co. purchased a new stake in United Therapeutics during the fourth quarter worth $217,000. Finally, First Trust Advisors LP lifted its holdings in United Therapeutics by 13.6% during the fourth quarter. First Trust Advisors LP now owns 1,196,804 shares of the biotechnology company’s stock worth $130,332,000 after buying an additional 143,235 shares during the period. Hedge funds and other institutional investors own 97.29% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: Fiduciary

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.